查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085494

子宮內膜異位症治療市場：依療法、給藥途徑、最終用戶和分銷管道分類－2026-2032年全球市場預測

Endometriosis Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，子宮內膜異位症治療市場將成長至 26.2 億美元，複合年成長率為 8.06%。

主要市場統計數據
基準年 2025 15.2億美元
預計年份：2026年 16.4億美元
預測年份 2032 26.2億美元
複合年成長率 (%) 8.06%

子宮內膜異位症治療市場概覽

子宮內膜異位症的治療正從控制症狀轉向早期診斷、長期疾病管理以及考慮生育能力的綜合治療方案。根據世界衛生組織（世衛組織）統計，該疾病影響全球約10%的育齡婦女和女孩，約1.9億人，是一種負擔沉重的婦科疾病，會對慢性骨盆疼痛、生產力、心理健康、性健康和生育結果產生重大影響。

子宮內膜異位症治療前景的變革性變化

子宮內膜異位症的治療方法正在轉變，從重複的經驗性治療轉向實證的個人化治療。歐洲人類生殖與胚胎學會（ESHRE）和英國國家衛生與臨床最佳化研究所（NICE）等機構近期發布的臨床指南強調與患者共同決策，並考慮症狀嚴重程度、懷孕目標、副作用、復發預防和長期後續觀察等因素，而非採用統一的治療策略。

人工智慧對子宮內膜異位症治療的累積影響

人工智慧（AI）正開始影響子宮內膜異位症治療的各個方面，包括診斷、臨床試驗設計、治療方案製定和患者後續觀察。利用人工智慧分析超音波影像和磁振造影（MRI）影像，有助於更準確地識別深部浸潤性子宮內膜異位症和卵巢內膜異位囊腫。此外，借助自然語言處理技術，或許可以從電子健康記錄識別出出現月經骨盆疼痛、經痛、性交疼痛、不孕症以及胃腸道和泌尿器官系統症狀模式的患者。

亞太地區、北美地區、歐洲地區、拉丁美洲地區以及中東和非洲地區的關鍵區域洞察

由於亞太地區擁有龐大的育齡人口、婦科醫療服務可及性不斷提高、慢性骨盆腔疼痛的診斷率不斷上升，以及中國、印度、日本、韓國和澳洲等國對該疾病的認知度不斷提高，該地區正成為子宮內膜異位症治療的重要發展區域。在日本和澳大利亞，微創婦科手術和影像技術已被廣泛應用，診斷和手術體係也較為成熟。同時，中國和印度憑藉著不斷擴大的都市區醫院網路、生育服務以及對女性健康的投入，展現出大規模的市場潛力。在東南亞部分地區，大城市專科醫療中心與醫療服務匱乏的農村地區之間仍然存在醫療資源分配不均的現象，這進一步凸顯了提供價格合理的診斷服務、加強臨床醫生培訓以及改善轉診管道的必要性。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約市場的關鍵群體分析

儘管東南亞國協的女性健康基礎設施正在不斷完善，但子宮內膜異位症的診斷仍然主要集中在都市區三級醫療機構和私立醫院，因此建立轉診網路和加強臨床醫生培訓對於早期治療至關重要。海灣合作理事會（GCC）市場的發展動力來自高昂的醫療保健支出、私立醫院容量的不斷擴大、醫療旅遊的日益興盛以及對先進生育治療和微創婦科服務的需求，所有這些因素都促進了高階診斷和手術技術以及專家主導的治療方案的引入。

主要子宮內膜異位症治療市場的關鍵國家特定洞察

美國在品牌治療藥物的普及、臨床試驗、患者權益倡導、骨盆疼痛專科護理和先進的腹腔鏡治療方面處於主導，而加拿大則側重於公共資助的醫療服務體系、省級醫療服務計劃以及為地理位置分散的人群提供公平的專科轉診服務。在墨西哥和巴西，隨著私人醫療保健、生育服務、婦科影像和微創手術的普及，需求正在成長，但自付費用、保險覆蓋範圍的差異以及專科醫生分佈不均仍然是獲得持續治療的重要障礙。

為子宮內膜異位症治療行業的領導者提供的實用建議

行業領導者應優先考慮能夠縮短診斷延遲、改善症狀管理、減輕復發負擔並保留生育選擇的解決方案。這包括投資於檢驗的非侵入性診斷方法、專門的影像學方案、患者報告結局 (PRO) 工具、人工智慧驅動的臨床決策支援系統，以及在安全性、耐受性、骨骼健康、藥物依從性和生活品質 (QOL) 方面具有明顯優勢的療法。

子宮內膜異位症治療分析的調查方法

本執行摘要採用二手研究方法，依據權威的公共來源編寫而成，包括世衛組織疾病負擔資訊、歐洲人類生殖與胚胎學會 (ESHRE) 和英國國家衛生與臨床最佳化研究所 (NICE) 臨床指南、美國食品藥品監督管理局 (FDA) 和歐洲藥品管理局 (EMA) 監管資訊披露、同行評審的婦科文獻、系統性回顧、公共衛生系統出版物以及公開的醫療保健資訊、同儕審查的婦科文獻、系統性回顧、公共衛生系統資訊來源以及公開資訊、同行評審的婦科文獻、系統性回顧、公共衛生系統調查方法

結論：實證子宮內膜異位症治療的進展

子宮內膜異位症的治療正朝著以患者為中心、技術驅動的方向發展，這主要受未被滿足的需求、慢性骨盆疼痛的負擔、對不孕不育的擔憂以及日益成長的生殖保健需求所驅動。治療選擇的拓展、微創手術技術的改進、影像技術的提升、多學科診療的開展以及人們對該疾病社會和經濟影響的認知不斷提高，都為這一領域的發展提供了支持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 子宮內膜異位症治療市場：依治療類型分類

  • 輔助療法
  • 荷爾蒙療法
    • Aromatase抑制劑
    • GnRH促效劑
    • GnRH拮抗劑
    • 口服避孕藥
    • 黃體素
  • 疼痛管理
    • NSAIDs
      • 雙氯芬酸鈉
      • Ibuprofen
      • 萘普生
    • 鴉片類藥物
      • 可待因
      • 氫可酮
  • 手術治療

第8章 子宮內膜異位症治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第9章 子宮內膜異位症治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第10章 子宮內膜異位症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 子宮內膜異位症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 子宮內膜異位症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 子宮內膜異位症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Anika Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Ferring International Center SA
  • Gedeon Richter Plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Merck & Co., Inc.
  • Myovant Sciences Ltd.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market is projected to grow by USD 2.62 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.52 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 2.62 billion
CAGR (%) 8.06%

Endometriosis Treatment Market Introduction

Endometriosis treatment is moving from symptom control toward earlier diagnosis, long-term disease management, and fertility-aware care pathways. The condition affects about 10% of reproductive-age women and girls worldwide, or roughly 190 million people, according to the World Health Organization, making it a high-burden gynecological disease with substantial implications for chronic pelvic pain, productivity, mental health, sexual health, and reproductive outcomes.

Demand for endometriosis drugs, minimally invasive surgery, diagnostics, and multidisciplinary care is reinforced by historically delayed diagnosis, recurrent symptoms, and the need to balance efficacy with safety. Industry participants are prioritizing non-opioid pain management, combined hormonal contraceptives, progestins, GnRH agonists and oral GnRH antagonists with add-back therapy, imaging-enabled diagnosis, and patient-centered care models that reduce time to appropriate treatment.

Transformative Shifts in the Endometriosis Treatment Landscape

The endometriosis treatment landscape is being reshaped by a shift away from repeated empirical treatment toward evidence-based, individualized care. Updated clinical guidance from organizations such as ESHRE and NICE emphasizes shared decision-making, symptom severity, fertility goals, adverse-effect profiles, recurrence prevention, and long-term follow-up rather than a one-size-fits-all pathway.

Transformative change is also visible in pharmacotherapy and surgical practice. Oral GnRH antagonists have expanded options beyond injectable suppression approaches, while laparoscopy continues to support lesion removal and diagnosis in appropriate patients, particularly for deep infiltrating disease, endometriomas, or infertility-related evaluation. At the same time, specialist ultrasound, MRI, multidisciplinary pelvic pain clinics, fertility-preservation counseling, and digital symptom tracking are improving continuity of care and strengthening treatment adherence.

Cumulative Impact of Artificial Intelligence on Endometriosis Care

Artificial intelligence is beginning to influence endometriosis care across diagnosis, trial design, treatment planning, and patient monitoring. AI-enabled analysis of ultrasound and MRI images may support more consistent identification of deep infiltrating endometriosis and ovarian endometriomas, while natural language processing can help identify patients with recurring pelvic pain, dysmenorrhea, dyspareunia, infertility, and gastrointestinal or urinary symptom patterns in electronic health records.

The cumulative impact of AI is most significant when it reduces diagnostic delay and improves treatment matching. Predictive models can support risk stratification, real-world evidence generation, clinical trial recruitment, and longitudinal monitoring of patient-reported outcomes. However, adoption depends on clinically validated algorithms, representative datasets, transparent performance reporting, clinician oversight, interoperability with care systems, and compliance with medical device, privacy, cybersecurity, and health equity requirements.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is emerging as a major development arena for endometriosis treatment due to large reproductive-age populations, improving access to gynecologic care, rising diagnosis of chronic pelvic pain, and increasing awareness in China, India, Japan, South Korea, and Australia. Japan and Australia have mature diagnostic and surgical ecosystems with strong use of minimally invasive gynecology and imaging, while China and India present high-volume opportunities as urban hospital networks, fertility services, and women's health investments expand. In parts of Southeast Asia, access continues to vary between metropolitan specialist centers and underserved rural areas, reinforcing the need for affordable diagnostics, clinician training, and referral pathway development.

North America remains a leading endometriosis treatment region supported by specialist access, advanced minimally invasive surgery, approved hormonal therapies, clinical research activity, and active patient advocacy. Europe benefits from structured clinical guidelines and reimbursement pathways, particularly across Germany, France, Italy, Spain, and the United Kingdom, with growing emphasis on multidisciplinary endometriosis centers and standardized imaging. Latin America is seeing rising demand in Brazil, Mexico, and other urban healthcare hubs as private care and fertility treatment expand, although affordability and uneven specialist distribution remain constraints. The Middle East is supported by expanding hospital infrastructure and demand for fertility and advanced gynecology services, particularly in higher-income health systems, while Africa faces significant underdiagnosis, specialist shortages, and access barriers that create a strong need for awareness, training, and scalable care models.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO Markets

ASEAN countries are strengthening women's health infrastructure, although endometriosis diagnosis often remains concentrated in urban tertiary centers and private hospitals, making referral networks and clinician education essential for earlier care. GCC markets benefit from high healthcare spending, expanding private hospital capacity, medical tourism ambitions, and demand for advanced fertility and minimally invasive gynecology services, supporting adoption of premium diagnostics, surgical techniques, and specialist-led treatment pathways.

The European Union provides a favorable environment for harmonized clinical standards, pharmacovigilance, post-market surveillance, and cross-border research collaboration, while national reimbursement and health technology assessment processes continue to shape access to therapies and procedures. BRICS countries represent scale and unmet clinical need, led by China, India, and Brazil, with Russia and South Africa reflecting more variable access conditions. G7 markets drive innovation through established regulatory systems, academic research, specialty care networks, and access to advanced pharmaceutical and surgical options. NATO countries overlap with several advanced healthcare markets where supply resilience, data governance, cybersecurity, and medical technology security increasingly influence healthcare strategy for digitally enabled endometriosis care.

Key Country Insights in Major Endometriosis Treatment Markets

The United States leads in branded therapy availability, clinical trials, patient advocacy, specialty pelvic pain care, and advanced laparoscopic treatment, while Canada emphasizes publicly funded care pathways, provincial access planning, and equitable specialist referral across geographically dispersed populations. Mexico and Brazil show rising demand as private healthcare, fertility services, gynecologic imaging, and minimally invasive surgery expand, though out-of-pocket costs, insurance coverage variation, and specialist concentration remain important barriers to consistent treatment access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are guided by strong clinical networks, reimbursement frameworks, specialist gynecology expertise, and growing awareness campaigns focused on reducing diagnostic delay. Germany and France benefit from advanced hospital infrastructure and structured care pathways, while the United Kingdom continues to emphasize guideline-led management and recognition of endometriosis as a long-term condition. Italy and Spain show strong surgical and reproductive medicine capabilities, and Russia presents demand for gynecologic care but faces system and access variability. China and India offer significant long-term development potential due to population scale, healthcare modernization, expanding women's health services, and rising fertility care demand. Japan, Australia, and South Korea combine high diagnostic capability with advanced minimally invasive surgery, specialist imaging, and women's health innovation, supporting evidence-based adoption of new endometriosis treatment approaches.

Actionable Recommendations for Endometriosis Treatment Industry Leaders

Industry leaders should prioritize solutions that shorten diagnostic delay, improve symptom control, reduce recurrence burden, and preserve fertility choices. This includes investment in validated noninvasive diagnostics, specialist imaging protocols, patient-reported outcome tools, AI-assisted clinical decision support, and therapies with clear safety, tolerability, bone-health, adherence, and quality-of-life advantages.

Commercial strategy should align with local reimbursement realities, treatment guidelines, and clinician education needs. Organizations can gain advantage by partnering with gynecologists, radiologists, fertility specialists, pain experts, primary care clinicians, payers, and patient advocacy groups to build integrated care pathways. Real-world evidence, health economics data, inclusive clinical trials, and region-specific access programs should be used to demonstrate value across diverse patient populations without relying on unsupported market claims.

Research Methodology for Endometriosis Treatment Analysis

This executive summary is developed using a secondary research methodology grounded in authoritative public sources, including WHO disease burden information, clinical guidance from ESHRE and NICE, regulatory information from FDA and EMA resources, peer-reviewed gynecology literature, systematic reviews, public health publications, and publicly available healthcare system disclosures.

Insights are synthesized through treatment pathway assessment, regional healthcare access analysis, technology adoption review, regulatory and reimbursement scanning, and evaluation of clinical practice trends. The methodology emphasizes verified evidence, triangulation across credible sources, and exclusion of unsupported market sizing, market share, and forecasting claims to ensure accuracy, relevance, and SEO-ready industry positioning for endometriosis treatment analysis.

Conclusion: Advancing Evidence-Based Endometriosis Treatment

Endometriosis treatment is entering a more patient-centered and technology-enabled phase, driven by unmet diagnostic needs, the burden of chronic pelvic pain, infertility concerns, and growing demand for fertility-conscious care. The sector is supported by expanding therapeutic options, improved minimally invasive surgical practice, stronger imaging capability, multidisciplinary care, and greater awareness of the disease's social and economic impact.

Future leadership will depend on evidence-based innovation, equitable access, and integrated care delivery. Organizations that combine validated diagnostics, effective therapies, real-world data, clinician education, and regional adaptation will be best positioned to improve outcomes and support sustainable progress in the global endometriosis treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endometriosis Treatment Market, by Treatment Type

  • 7.1. Complementary Therapies
  • 7.2. Hormonal Therapies
    • 7.2.1. Aromatase Inhibitors
    • 7.2.2. Gnrh Agonists
    • 7.2.3. Gnrh Antagonists
    • 7.2.4. Oral Contraceptives
    • 7.2.5. Progestins
  • 7.3. Pain Management
    • 7.3.1. Nsaids
      • 7.3.1.1. Diclofenac
      • 7.3.1.2. Ibuprofen
      • 7.3.1.3. Naproxen
    • 7.3.2. Opioids
      • 7.3.2.1. Codeine
      • 7.3.2.2. Morphine
  • 7.4. Surgical Treatment

8. Endometriosis Treatment Market, by Route Of Administration

  • 8.1. Injectable
  • 8.2. Oral
  • 8.3. Topical

9. Endometriosis Treatment Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Endometriosis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Endometriosis Treatment Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Endometriosis Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Endometriosis Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Amneal Pharmaceuticals Inc.
  • 15.3. Anika Therapeutics, Inc.
  • 15.4. Astellas Pharma Inc.
  • 15.5. AstraZeneca plc
  • 15.6. Bayer AG
  • 15.7. Eli Lilly and Company
  • 15.8. Ferring International Center S.A.
  • 15.9. Gedeon Richter Plc
  • 15.10. Johnson & Johnson Services, Inc.
  • 15.11. Kissei Pharmaceutical Co., Ltd.
  • 15.12. Livzon Pharmaceutical Group Inc.
  • 15.13. Merck & Co., Inc.
  • 15.14. Myovant Sciences Ltd.
  • 15.15. Neurocrine Biosciences, Inc.
  • 15.16. Novartis AG
  • 15.17. ObsEva SA
  • 15.18. Pfizer Inc.
  • 15.19. Repros Therapeutics Inc.
  • 15.20. Sanofi S.A.
  • 15.21. Shionogi & Co., Ltd.
  • 15.22. Takeda Pharmaceutical Company Limited
  • 15.23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GNRH AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GNRH AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GNRH AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGESTINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROGESTINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGESTINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DICLOFENAC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DICLOFENAC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DICLOFENAC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IBUPROFEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IBUPROFEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IBUPROFEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NAPROXEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NAPROXEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NAPROXEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MORPHINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MORPHINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MORPHINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 321. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 322. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)